Orchard Therapeutics (ORTX), a global gene therapy leader, today announced the appointment of Steven Altschuler, M.D., to its board of directors. Dr. Altschuler brings nearly 20 years of experience building and leading world-class, integrated, translational, value-based health care systems and transformational biotechnology companies. “Steven joins Orchard at an exciting and pivotal time as we prepare for the anticipated EU regulatory approval of our investigational gene therapy for metachromatic leukodystrophy, as well as four additional regulatory filings in the U.S. and Europe that are expected by 2021,” said Mark Rothera, president and chief executive officer of Orchard.
Orchard Therapeutics (ORTX), a global leader in gene therapy, today provided an update on its business and operations, outlining how the COVID-19 pandemic has and may continue to impact the company’s development programs and timelines, product supply, commercial operations and financial position. Orchard has taken important steps to help ensure the safety of employees and their families and reduce spread of the virus in the communities where the company operates. “We are operating in an unprecedented time for our business and the industry as a whole, given the rapid and global spread of COVID-19,” said Bobby Gaspar, chief executive officer of Orchard.
Shares of Orchard Therapeutics (NASDAQ:ORTX) fell 1.5% after the company reported Q1 results.Quarterly Results Earnings per share decreased 45.71% over the past year to ($0.51), which were in line with the estimate of ($0.51).Revenue of $0 unchanged by 0.00% from the same period last year, which missed the estimate of $490,000.Outlook Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: May 07, 2020View more earnings on ORTXTime: 11:01 PM ETWebcast URL: https://edge.media-server.com/mmc/p/h3uyhwmiRecent Stock Performance Company's 52-week high was at $20.5052-week low: $5.17Price action over last quarter: down 10.36%Company Profile Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integrated biopharmaceutical company. The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. It operates in three geographic regions: the United Kingdom, European Union, and the United States. Orchard Rx is focusing on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, used for the treatment of ADA-SCID five lentiviral product candidates.See more from Benzinga * Perficient: Q1 Earnings Insights * Mednax: Q1 Earnings Insights * Endo International: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ladies and gentlemen, thank you for standing by, and welcome to the Orchard Therapeutics First Quarter 2020 Investor Conference Call. Before we get started, I'd like to remind everyone that statements we make on this call will include forward-looking statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risk factors and uncertainties, and including those set forth in our annual 10-K filed with the SEC and any other filings we may make.
Orchard Therapeutics (ORTX), a global gene therapy leader, today announced a new strategic plan to realize the potential of the hematopoietic stem cell (HSC) gene therapy approach and reported its financial results for the quarter ended March 31, 2020. “I feel privileged to lead Orchard as we embark on this new chapter, which is rooted in fulfilling the powerful possibilities for HSC gene therapies beyond ultra-rare diseases,” said Bobby Gaspar, M.D., Ph.D., chief executive officer.
Orchard Therapeutics (ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, May 7, 2020, at 8:00 a.m. ET to report its first quarter 2020 financial results and other business updates. A live webcast will be available under "News & Events" in the Investors & Media section of the company's website at orchard-tx.com. A replay of the webcast will be archived on the Orchard website following the presentation.
Live webcasts of the presentations will be available under "News & Events" in the Investors & Media section of the company's website at www.orchard-tx.com. Webcast replays will be archived on the Orchard website following the presentation. Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies.
NEW YORK, NY / ACCESSWIRE / February 27, 2020 / Orchard Therapeutics Plc (NASDAQ:ORTX) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 27, 2020 ...
BOSTON and LONDON, Feb. 10, 2020 -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced upcoming presentations from its neurometabolic franchise.
Commercial Preparations on Track for Potential Second Half 2020 EU Launch of OTL-200 for MLD with U.S. Regulatory Filing Expected Late 2020 / Early 2021 Initiation of Rolling.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
Orchard Therapeutics (ORTX), a global gene therapy leader, today announced that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for OTL-102, the company’s ex vivo autologous hematopoietic stem cell (HSC) gene therapy being investigated for the treatment of X-linked chronic granulomatous disease (X-CGD). The FDA may grant orphan designation to drugs and biologics intended to treat a rare disease or condition affecting fewer than 200,000 persons in the U.S.
BOSTON and LONDON, Feb. 26, 2020 -- Orchard Therapeutics (Nasdaq: ORTX), a global leader in gene therapy, today announced that members of the management team will present at.
Orchard Therapeutics (ORTX), a global gene therapy leader, today announced new interim data from an ongoing proof-of-concept clinical trial evaluating the safety and efficacy of OTL-203, an ex vivo autologous hematopoietic stem cell (HSC) gene therapy in development for the treatment of mucopolysaccharidosis type I (MPS-I) at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy. As of April 2020, all eight patients with the severe Hurler subtype of MPS-I have been treated with OTL-203.
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Orchard Therapeutics (ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, February 27, 2020, at 8:00 a.m. ET to report its 2019 financial results and other business updates. A live webcast will be available under "News & Events" in the Investors & Media section of the company's website at orchard-tx.com. The conference call can be accessed by dialing (866) 930-5155 (U.S. domestic) or +1-(409) 937-8974 (international) and referring to conference ID 8096875.
The latest analyst coverage could presage a bad day for Orchard Therapeutics plc (NASDAQ:ORTX), with the analysts...
BOSTON and LONDON, April 27, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a global gene therapy leader, today announced that the first patient has been dosed in an open-label, proof-of-concept investigational study of OTL-201, an ex vivo autologous hematopoietic stem cell (HSC) gene therapy for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA). The study also contains a number of key secondary outcome measures such as overall survival, cognition and behavior to help inform future clinical development of HSC gene therapy in this indication. MPS-IIIA, also known as Sanfilippo syndrome type A, is a rare, inherited neurometabolic disorder caused by genetic mutations that leads to the buildup of sugar molecules called mucopolysaccharides in the body, resulting in progressive intellectual disability and loss of motor function.
Orchard Therapeutics (ORTX), a global gene therapy leader, today announced that company founder and gene therapy pioneer Bobby Gaspar, M.D., Ph.D., has been named chief executive officer, effective immediately. Dr. Gaspar, previously president of research, chief scientific officer, and a member of the Orchard board of directors, succeeds Mark Rothera, who has served as the company’s chief executive officer since 2017.
BOSTON and LONDON, April 29, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a global gene therapy leader, today announced eight upcoming presentations from across its neurometabolic, primary immune deficiency and blood disorder franchises at the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting, which will take place online May 12-15, 2020, marking the company’s most comprehensive presentation of clinical data at a medical meeting to date. Accepted abstracts include data on three investigational treatments to address various neurometabolic disorders, including mucopolysaccharidosis type I (MPS-I), with high unmet need.